What’s driving Moderna higher today (January 5)?

Traders Union
All News
Financial News
Moderna Surges 5.22% Today

Highlights

Moderna submitted marketing authorization applications for its mRNA-1010 seasonal influenza vaccine on January 5, 2026, in the US, EU, Canada, and Australia.
Phase 3 clinical data showed mRNA-1010 achieved over 26% relative efficacy in adults aged 50 and older compared to traditional flu vaccines.
mRNA-1010 demonstrated superior immunogenicity to currently licensed influenza vaccines, marking a major advancement for Moderna's vaccine pipeline.

Vaccine approval filings drive optimism on regulatory progress

On January 5, 2026, Moderna submitted marketing authorization applications for its investigational seasonal influenza vaccine, mRNA-1010, in the United States, European Union, Canada, and Australia. The filings are supported by positive Phase 3 clinical data, including a relative efficacy of over 26% in adults aged 50 and older, and demonstrated superior immunogenicity compared to currently licensed influenza vaccines. This milestone marks a significant regulatory step forward for Moderna's vaccine pipeline.

Anton Kharitonov, expert at Traders Union, notes that Moderna remains in a short-term uptrend above all key moving averages, but warns this strength may be overstated by momentum signals. He points out that technical divergences — especially the oversold Stoch RSI and neutral CCI — reveal underlying fragility and mixed conviction among buyers. Despite the positive regulatory news, he is wary that relative efficacy near 26% for the new vaccine does not guarantee broad market adoption or outperformance. Kharitonov also cautions that a drop below $30.00 would sharply shift sentiment and invite stronger selling pressure. "Until I see confirmation above $33.50 with improving internals, I view current gains as vulnerable to reversal."

Viktoras Karapetjanc, expert at Traders Union, believes Moderna's regulatory filings mark a clear leap forward for its vaccine pipeline and long-term growth profile. He sees robust price action supported by bullish momentum and constructive sentiment as institutions respond to strong Phase 3 results. The recent technical breakout above all major moving averages suggests further upside remains achievable in the near term. "With bullish structure intact and regulatory catalysts unfolding, I expect Moderna to deliver further growth opportunities for investors this week."

Jainam Mehta, market strategist, views Moderna’s current setup as defined by short-term momentum but cautions against chasing strength at session highs. He notes the divergence between bullish MACD/ADX and the neutral-to-oversold readings in CCI and Stoch RSI, which could create tactical pullback or consolidation setups. Mehta sees the $32.00 to $33.50 range as a critical zone for mean reversion or breakout entries. "A confirmed push above $33.50 could signal the next leg up, but any loss of $30.00 may trigger quick downside as sentiment cools."

Bullish momentum prevails despite mixed technical divergences

Momentum signals are largely constructive: the MACD and ADX show strong bullish tendencies, while the RSI remains in modestly bullish territory. However, Stoch RSI signals an oversold condition, and CCI is neutral, producing some divergence in signals. BBP indicates buyer dominance today, with the Awesome Oscillator neutral. The stock opened higher than yesterday’s close, creating a small gap, and trading is currently at the upper end of today’s range amid moderate volatility. Intraday tone favors continued strength toward session highs, and short-term momentum supports the day’s upward move.

Last time, analysts noted that MRNA sustained a bullish structure above key moving averages despite mixed momentum signals, as indicators such as MACD and ADX pointed to strengthening upside while CCI and oscillators reflected market indecision. Immediate dynamic support was identified near the Ichimoku Kijun, with resistance found just below the psychologically significant level, and momentum indicators are mixed suggesting short-term caution as the price approached overhead resistance.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.